Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2/PHASE3
80 participants
INTERVENTIONAL
2017-01-01
2017-10-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
vaginal progestrone group
cohort of patients who received 400mg vaginal progestrone .
A complete Doppler flow assessment of the maternal and fetal circulation
A complete Doppler flow assessment of the maternal and fetal circulation was conducted by an independent investigator blinded to the treatment, 48 hours after receiving 400mg of vaginal progestrone .Voluson E8 (GE Healthcare, Zipf, Austria) ultrasound machine ,equipped with a 3.5-MHz curvilinear abdominal transducer with color imaging capabilities, was used in all cases.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
A complete Doppler flow assessment of the maternal and fetal circulation
A complete Doppler flow assessment of the maternal and fetal circulation was conducted by an independent investigator blinded to the treatment, 48 hours after receiving 400mg of vaginal progestrone .Voluson E8 (GE Healthcare, Zipf, Austria) ultrasound machine ,equipped with a 3.5-MHz curvilinear abdominal transducer with color imaging capabilities, was used in all cases.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Willing and able to give informed consent
* History of preterm labor (\<34 weeks)
* At risk for preterm labor ( increased amniotic fluid volume)
* Short cervical length (\<25mm) as incidental finding
* Presenting with actual cervical changes ( dilatation and\\or effacement) in current pregnancy
Exclusion Criteria
* Contraindication to progesterone use
* Diabetic patients, have glucose intolerance
* Multiple pregnancies
18 Years
40 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Kasr El Aini Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
sarah mohamed hassan
lecturer of obstetrics and gynecology Cairo university
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Kasr El Ainiy Hospital
Cairo, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
7880
Identifier Type: -
Identifier Source: org_study_id